208934-35-4

Usage

Uses

Used in Chemical Research and Experiments:
4-(Tributylstannyl)-1-tritylimidazole is used as a reagent for the synthesis of various compounds through different types of synthesis reactions. Its unique structure and properties make it a valuable tool in the development of new chemical entities.
Used in Safety Protocols:
Due to its potential biological, health, and environmental hazards, 4-(Tributylstannyl)-1-tritylimidazole is recognized for its toxicity. As a result, it is used as a reference point for establishing safety protocols in scientific laboratory settings to ensure the safe handling and disposal of 4-(Tributylstannyl)-1-tritylimidazole. This is crucial for minimizing the risks associated with its use and for protecting the health of researchers and the environment.

InChI:InChI=1/C22H17N2.3C4H9.Sn/c1-4-10-19(11-5-1)22(24-17-16-23-18-24,20-12-6-2-7-13-20)21-14-8-3-9-15-21;3*1-3-4-2;/h1-15,17-18H;3*1,3-4H2,2H3;/rC34H44N2Sn/c1-4-7-25-37(26-8-5-2,27-9-6-3)33-28-36(29-35-33)34(30-19-13-10-14-20-30,31-21-15-11-16-22-31)32-23-17-12-18-24-32/h10-24,28-29H,4-9,25-27H2,1-3H3

Upstream product

• 925-90-6 ethylmagnesium bromide 
• 1461-22-9 tributyltin chloride 
• 96797-15-8 N-trityl-4⁽⁵⁾-iodoimidazole 
• 76-83-5 trityl chloride 
• 920-39-8 isopropylmagnesium bromide 

Downstream Products

• 862500-53-6 2-(1-trityl-1H-imidazol-4-yl)-thiazole-5-carboxylic acid methyl ester 
• 179759-77-4 hydroxy-(1-trityl-1H-imidazol-4-yl)acetic acid ethyl ester 
• 153684-73-2 4-(pyridin-2-yl)-1-trityl-1H-imidazole 
• 925884-39-5 5-[2-(-1-triphenyl methylimidazol-4-yl)pyrid-5-yl]-1-azabicyclo[3.2.1]oct-3-ene 
• 942189-40-4 5-nitro-1-trityl-3-(1-trityl-1H-imidazol-4-yl)-1H-indazole 

Relevant academic research and scientific papers

COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF

The present invention provides KDM5 inhibitor. The compound disclosed herein represented by the general formula (Z): wherein all symbols have the same meanings as the definitions described in the specification; or a salt thereof is useful as a prophylactic and/or therapeutic agent for cancer, Huntington's disease, or Alzheimer's disease and the like.

COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE

The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of IDO, and for the treatment of IDO-related disorders.

FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF

This disclosure is related to a fused-ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the fused ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, preparation methods thereof, and use thereof in modulating activity of indoleamine 2, 3-dioxygenase (IDO) and/or tryptophan 2, 3-dioxygenase (TDO). This disclosure further provides methods of treating IDO and/or TDO-associated diseases, including cancer, viral infection and autoimmune diseases.

ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS

The present invention is directed to compounds of formula (I), wherein R1 is a ring and n is a number from 1 to 8. The invention also relates to use of the compounds in therapy as metabotropic glutamate receptor modulators, particularly in neurological and psychiatric disorders.

THIAZOLYL-HYDROXAMIC ACIDS AND THIADIAZOLYL-HYDROXAMIC ACIDS, AND USE THEREOF FOR TREATING DISEASES ASSOCIATED WITH HISTONE DEACETYLASE ENZYMATIC ACTIVITY

A compound of formula: (I) in which A represents optionally substituted monocyclic heteroaryl or phenyl; B represents optionally substituted heteroaryl, aryl, aryl-fused-heterocycloalkyl, heteroaryl-fused-cycloalkyl, heteroaryl-fused-heterocycloalkyl or aryl-fused-cycloalkyl, or B represents H when L represents a single bond; L represents a single bond, alkylene, (CH2)nX(CH2)m, (CH2)nX(CH2)pY(CH2)m; Q represents N or CR2; T represents N or CR2, provided that Q and T do not both represent CR2 simultaneously; X represents -O-, -NR3-, -CO-, -SO2-, -NR3C0-, -NR3SO2-, -CONR3-, -SO2NR3-, -NR1CONR1-; Y represents -NR3- or -O-; Rl represents H or alkyl; R2 represents hydrogen, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, CN; R3 represents H, alkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, cycloalkylalkyl, or alkyl substituted by -OR4, -NR5R6, -NR6COR7, -NR6SO2R7, -CONR5R6 or -SO2NR5R6; R4 represents H, alkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl or cycloalkyl; R5 represents H or alkyl; R6 represents H, alkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl or cycloalkyl or NR5R6 represents a cyclic amine; R7 represents alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl; n represents 0-3; m represents 0-3; p represents 1-3; and corresponding N-oxides, pharmaceutically acceptable salts, solvates and prodrugs thereof; and use to treat a disease in which inhibition of histone deacetylase can prevent, inhibit or ameliorate the pathology and/or symptomatology of the disease.

Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

The present invention provides compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.

3-Azabicyclo[3.1.0]hexane derivatives useful in therapy

Compounds of formula (I), their salts and prodrugs thereof, where the substituents are as defined herein are disclosed as opiate binding agents useful in the treatment of opiate-mediated conditions. Also described are processes for making such substances.